(P018) Micronucleus Score in Buccal Smear of Premalignant Lesions of Oral Cancers in Smokers

Publication
Article
OncologyOncology Vol 28 No 1S
Volume 28
Issue 1S

Oral squamous cell carcinoma encompasses 90% of all oral malignancies. It is considered the sixth most common malignancy and is a major cause of cancer morbidity and mortality worldwide. Early detection of premalignant lesions or cancerous oral lesions would improve the survival to a greater extent.

Rijuneeta Gupta, MS, MD, Aniruddha Sarkar, MS, MD, Ashok Gupta, MS, MD, Pranab Dey, MD, Uma Nahar, MD; Department of Ear Nose and Throat, Post Graduate Institute of Medical Education and Research (PGIMER)

Introduction: Oral squamous cell carcinoma encompasses 90% of all oral malignancies. It is considered the sixth most common malignancy and is a major cause of cancer morbidity and mortality worldwide. Early detection of premalignant lesions or cancerous oral lesions would improve the survival to a greater extent.

The micronucleus (MN) is the small fragment of the nucleus situated around the periphery of the main nucleus. The number of micronucleated cells (MNCs) per 1,000 epithelial cells in oil immersion magnification (1,000 ×) is known as MN score. The MN score from buccal mucosa may be helpful in detecting premalignant lesions of the oral cavity in smokers.

Objectives: To evaluate the role of MN score in buccal smears of premalignant lesions of the oral cavity in smokers.

Materials and Methods: It was a prospective cross-sectional study including 60 patients with ages ranging from 15–70 years. They were divided into three groups. Group 1 (control) included 20 nonsmokers with lesions other than premalignant lesions, Group 2 included 20 smokers with lesions other than premalignant lesions, and Group 3 included 20 smokers with premalignant conditions of the oral cavity.

In each patient, smears were taken from the lesion with the help of sterile, clean, blunt scalpel blades. Smears were immediately seen under a fluorescent microscope, and MNCs were counted per 1,000 epithelial cells. In all patients, a biopsy was also done.

Chronic alcoholics, postradiotherapy cases, and cases exposed to any cytotoxic drug were excluded from the study.

Observations: Overall, 85% was male and 15% was female. Mean MN scores in all groups (acridine orange stain) were 0.1052, 0.2725, and 0.855, respectively. Mean scores for Groups 1, 2, and 3 in Papanicolaou staining were 0.1365, 0.395, and 1.12, respectively. Pearson’s correlation coefficient was done between smoking and MN score. Smoking was found to be positively correlated to MN score in both Papanicolaou and acridine orange smears.

Histopathological examination showed no evidence of malignancy in Groups 1 and 2. Group 3 showed histopathological evidence of leukoplakia (85%), lichen planus (5%), keratosis (5%), and papilloma (5%).

MN score was not statistically significant between Group 1 and Group 2 (P > .5). However, MN score was highly statistically significant (P < .0001) between Group 2 and Group 3 and also between Group 1 and Group 3.

Conclusions: We found a gradual increase in MN score from nonsmokers with no premalignant lesions (Group 1) to smokers with no premalignant lesions (Group 2) and smokers with premalignant lesions (Group 3). MN scoring can be used as a biomarker for screening premalignant conditions.

Articles in this issue

(P113) Age and Marital Status Are Associated With Choice of Mastectomy in Patients Eligible for Breast Conservation Therapy
(P112) Single-Institution Experience With Intrabeam IORT for Treatment of Early-Stage Breast Cancer
(P110) Breast Cancer Before Age 40: Current Patterns in Clinical Presentation and Local Management
(P111) Accelerated Partial-Breast Irradiation With Multicatheter High-Dose-Rate Brachytherapy: Feasibility and Results in a Private Practice Cohort
(P115) Breast Cancer Laterality Does Not Influence Overall Survival in a Large Modern Cohort: Implications for Radiation-Related Cardiac Mortality
(P117) Anatomical Variations and Radiation Technique for Breast Cancer
(P116) Bilateral Immediate DIEP Reconstruction and Postmastectomy Radiotherapy: Experience at a Tertiary Care Institution
(P118) Metadherin Overexpression Is Associated With Improved Locoregional Control After Mastectomy
(P119) Effect of Economic Environment on Use of Postlumpectomy Radiation Therapy for Stage I Breast Cancer
(P120) Immediate Versus Delayed Reconstruction After Mastectomy in the United States Medicare Breast Cancer Patient
(P121) Trend in Age and Racial Disparities in the Receipt of Postlumpectomy Radiation Therapy for Stage I Breast Cancer: 2004–2009
(P122) Streamlining Referring Physicians Orders With ‘Reflex Testing’ Significantly Decreases Time to Resolution for Abnormal Screening Mammograms
(P123) National Trends in the Local Management of Early-Stage Paget Disease of the Breast
(P124) Effect of Inhomogeneity on Cardiac and Lung Dose in Partial-Breast Irradiation Using HDR Brachytherapy
(P125) Breast Cancer Outcomes With Anthracycline-Based Chemotherapy for Residual Disease Burden After Full-Dose Neoadjuvant Chemotherapy and Surgery Followed by Radiation Treatment
Recent Videos
The investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.
Management of adverse effects and access to cellular therapies among community oncologists represented key points of discussion in multiple myeloma.
“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.
Treatment with the dual inhibitor displayed a short half-life and a manageable toxicity profile in patients with clear cell renal cell carcinoma.
The annual Kidney Cancer Research Summit was born from congressional funding for kidney cancer research, according to KidneyCAN president Bryan Lewis.
Combining renal vaccines with immune therapy may better target tumor cells while limiting harm to healthy tissue, according to David A. Braun, MD, PhD.
Improving data collection and biomarker development across institutions may represent areas of expansion in kidney cancer research.
KIM-1 is a biomarker in the blood that may help noninvasively detect kidney cancer, according to Wenxin (Vincent) Xu, MD.
A phase 0 trial is seeking to assess the feasibility of aiding anti-cancer cells with cytokines to restore their function.
Although pembrolizumab addressed a long-standing need in adjuvant kidney cancer treatment, combinations with the agent may further bolster efficacy.
Related Content